Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases

Patel, Chirag; Pande, Sonal; Sagathia, Vrunda; Ranch, Ketan M.; Beladiya, Jayesh V.; Boddu, Sai H. S.; Jacob, Shery; Al-Tabakha, Moawia M.; Hassan, Nageeb; Shahwan, Moyad

doi:10.3390/pharmaceutics15030837

Cited by 8 publications

(4 citation statements)

References 226 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanocarriers may become a useful tool to deliver drugs intra-ocularly with limited invasive technology to minimize the burden for patients. 102 We discuss in the next chapters whether local administration in the eye of inhibitors of ATP synthesis via glycolysis and/or OXPHOS may be a realistic therapeutic approach.…”

Section: Physiological and Pathological Angiogenesismentioning

confidence: 99%

New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases

van Noorden,

Yetkin-Arik,

Serrano Martinez

et al. 2024

J Histochem Cytochem.

View full text Add to dashboard Cite

Lactate and ATP formation by aerobic glycolysis, the Warburg effect, is considered a hallmark of cancer. During angiogenesis in non-cancerous tissue, proliferating stalk endothelial cells (ECs) also produce lactate and ATP by aerobic glycolysis. In fact, all proliferating cells, both non-cancer and cancer cells, need lactate for the biosynthesis of building blocks for cell growth and tissue expansion. Moreover, both non-proliferating cancer stem cells in tumors and leader tip ECs during angiogenesis rely on glycolysis for pyruvate production, which is used for ATP synthesis in mitochondria through oxidative phosphorylation (OXPHOS). Therefore, aerobic glycolysis is not a specific hallmark of cancer but rather a hallmark of proliferating cells and limits its utility in cancer therapy. However, local treatment of angiogenic eye conditions with inhibitors of glycolysis may be a safe therapeutic option that warrants experimental investigation. Most types of cells in the eye such as photoreceptors and pericytes use OXPHOS for ATP production, whereas proliferating angiogenic stalk ECs rely on glycolysis for lactate and ATP production. (J Histochem Cytochem XX.XXX–XXX, XXXX)

show abstract

Section: Physiological and Pathological Angiogenesismentioning

confidence: 99%

New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases

van Noorden,

Yetkin-Arik,

Serrano Martinez

et al. 2024

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…In addition to the hydrophobic interactions and electrostatic, charge transfer interactions and hydrogen bonding may also contribute to the binding activities [ 22 ]. Several lines of evidence have shown that melanin can interact with drug molecules and influence their distribution in the posterior segment of the eye [ 23 ].…”

Section: Biological Barriers To Ocular Drug Deliverymentioning

confidence: 99%

Biodegradable microspheres come into sight: A promising biomaterial for delivering drug to the posterior segment of the eyeball

Xue,

Wu,

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

“… Barriers to ocular drug delivery along with routes of ocular drug delivery. Reproduced with permission from Patel C et al, 132 CC BY 4.0. …”

Section: Strategies To Enhance the Ocular Bioavailability Of Proteins...mentioning

confidence: 99%

An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye

Boddu,

Acharya,

Hala

et al. 2023

ACS Omega

Self Cite

View full text Add to dashboard Cite

In the past few decades, advancements in protein engineering, biotechnology, and structural biochemistry have resulted in the discovery of various techniques that enhanced the production yield of proteins, targetability, circulating half-life, product purity, and functionality of proteins and peptides. As a result, the utilization of proteins and peptides has increased in the treatment of many conditions, including ocular diseases. Ocular delivery of large molecules poses several challenges due to their high molecular weight, hydrophilicity, unstable nature, and poor permeation through cellular and enzymatic barriers. The use of novel strategies for delivering protein and peptides such as glycoengineering, PEGylation, Fc-fusion, chitosan nanoparticles, and liposomes have improved the efficacy, safety, and stability, which consequently expanded the therapeutic potential of proteins. This review article highlights various proteins and peptides that are useful in ocular disorders, challenges in their delivery to the eye, and strategies to enhance ocular bioavailability using novel delivery approaches. In addition, a few futuristic approaches that will assist in the ocular delivery of proteins and peptides were also discussed.

show abstract

Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases

Cited by 8 publications

References 226 publications

New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases

New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases

Biodegradable microspheres come into sight: A promising biomaterial for delivering drug to the posterior segment of the eyeball

An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye

Contact Info

Product

Resources

About